Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T13:40:53.376Z.
Consensus retrieved: 2026-10-06T08:54:38.083Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T13:40:53.376Z.
Quote observation: 2026-10-06T13:40:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: adca945f375d0863f0f013440b023eebfab0caffb47005764e85a23fe93f72ce
Forward PE Ratio (N/A) = Dated Quote Price ($4.55) / Consensus Forward EPS ($-0.49)
FORWARD PE RATIO
N/A
Aquestive Therapeutics, Inc.
Market Cap
$570.87M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | $570.87M | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $568.83M | N/A |
| CorMedix Inc. (CRMD)vs › | $566.22M | 14.58 |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $575.41M | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $557.32M | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $548.86M | N/A |
| OrthoPediatrics Corp. (KIDS)vs › | $593.84M | N/A |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $596.64M | 2.96 |
| Immix Biopharma, Inc. (IMMX)vs › | $541.30M | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $534.87M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $4.55, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.49 | $-0.58 – $-0.42 | 4 | n/m |
| 2027-12-31 | $-0.50 | $-0.60 – $-0.39 | 4 | n/m |
| 2028-12-31 | $-0.37 | $-0.55 – $-0.25 | 3 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
